181 related articles for article (PubMed ID: 23132335)
1. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Buijs M; Reyes DK; Pawlik TM; Blackford AL; Salem R; Messersmith WA; Weekes CD; Mulcahy M; Kamel IR; Geschwind JF
Cancer; 2013 Mar; 119(5):1042-9. PubMed ID: 23132335
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.
Britten CD; Gomes AS; Wainberg ZA; Elashoff D; Amado R; Xin Y; Busuttil RW; Slamon DJ; Finn RS
BMC Cancer; 2012 Jan; 12():16. PubMed ID: 22244160
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Pawlik TM; Reyes DK; Cosgrove D; Kamel IR; Bhagat N; Geschwind JF
J Clin Oncol; 2011 Oct; 29(30):3960-7. PubMed ID: 21911714
[TBL] [Abstract][Full Text] [Related]
7. Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases.
Wang X; Yang Y
Medicine (Baltimore); 2024 May; 103(20):e38174. PubMed ID: 38758900
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.
Wang K; Yu HM; Xiang YJ; Cheng YQ; Ni QZ; Guo WX; Shi J; Feng S; Zhai J; Cheng SQ
Future Oncol; 2022 Sep; 18(30):3367-3375. PubMed ID: 35968836
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Park JW; Koh YH; Kim HB; Kim HY; An S; Choi JI; Woo SM; Nam BH
J Hepatol; 2012 Jun; 56(6):1336-42. PubMed ID: 22314421
[TBL] [Abstract][Full Text] [Related]
12. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
[TBL] [Abstract][Full Text] [Related]
13. 131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.
Ma J; Wang JH
Asian Pac J Cancer Prev; 2015; 16(17):7441-7. PubMed ID: 26625741
[TBL] [Abstract][Full Text] [Related]
14. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
15. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients.
Wu L; Yang YF; Ge NJ; Shen SQ; Liang J; Wang Y; Zhou WP; Shen F; Wu MC
Cancer Biother Radiopharm; 2010 Dec; 25(6):657-63. PubMed ID: 21204759
[TBL] [Abstract][Full Text] [Related]
17. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma.
Cheng JC; Chuang VP; Cheng SH; Huang AT; Lin YM; Cheng TI; Yang PS; You DL; Jian JJ; Tsai SY; Sung JL; Horng CF
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):435-42. PubMed ID: 10802371
[TBL] [Abstract][Full Text] [Related]
18. Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience.
Liu Y; Zhang Y; Bautista D; Tang S; Zhou J; Li C; Zhao G
Cell Biochem Biophys; 2015 Jan; 71(1):99-104. PubMed ID: 25323562
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Siegel AB; Cohen EI; Ocean A; Lehrer D; Goldenberg A; Knox JJ; Chen H; Clark-Garvey S; Weinberg A; Mandeli J; Christos P; Mazumdar M; Popa E; Brown RS; Rafii S; Schwartz JD
J Clin Oncol; 2008 Jun; 26(18):2992-8. PubMed ID: 18565886
[TBL] [Abstract][Full Text] [Related]
20. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
Chiang CL; Chan MKH; Yeung CSY; Ho CHM; Lee FAS; Lee VWY; Wong FCS; Blanck O
Strahlenther Onkol; 2019 Mar; 195(3):254-264. PubMed ID: 30413833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
